A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid
about
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsHow to manage aspergillosis in non-neutropenic intensive care unit patientsVoriconazole treatment of Candida tropicalis meningitis: persistence of (1,3)-β-D-glucan in the cerebrospinal fluid is a marker of clinical and microbiological failure: A case report.Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain.In vitro study of the variable effects of proton pump inhibitors on voriconazoleIsavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Intrathecal Amphotericin B: A 60-Year Experience in Treating Coccidioidal Meningitis.An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs.Development of a liquid chromatography tandem mass spectrometry method for the simultaneous measurement of voriconazole, posaconazole and itraconazole.Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.Need of voriconazole high dosages, with documented cerebrospinal fluid penetration, for treatment of cerebral aspergillosis in a 6-month-old leukaemic girl.The Novel Fungal Cyp51 Inhibitor VT-1598 is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.
P2860
Q26771180-351E7A7B-1939-4B98-853E-65AAAAA7BE44Q26999448-0A05B5A9-5AD9-4961-9365-1FD7DEA29E56Q30376282-7624DD48-B582-48BB-A450-B5869560C06BQ33764269-E9FE5B2D-8982-4402-83ED-E15A06B81A5AQ35152691-D04E5AEC-DDE9-4C44-A29B-8FC0D37D767CQ35960842-314F91E7-D3EA-4403-BD46-1F68623AAB3CQ37096795-99AA12C3-CD43-4C15-ACCA-85A5B32BEDC7Q39032299-691D5B2A-8E97-4FB5-B156-DC2B10DB2F03Q39466921-E173684F-63A2-4DA3-8FEB-05A6F7DAD97DQ40306219-F9AF5A9D-D1F4-432A-A168-EABC695467D2Q40323166-82FC732C-6F61-4FFF-854D-89B6951D38ADQ40414215-5178EFEB-757F-430D-99DF-8F4F0E90EDBDQ40474311-AB8D2218-6D71-4963-BC05-48CE5556FA6FQ41284722-20B96BD9-1983-4A3E-8347-4B870280F083Q41444763-C693C195-D729-416C-8B44-7E828DA484E1Q50044363-A458256A-31E3-488E-936C-8067B2BE11D3
P2860
A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A reference laboratory experie ...... ream and cerebral spinal fluid
@en
type
label
A reference laboratory experie ...... ream and cerebral spinal fluid
@en
prefLabel
A reference laboratory experie ...... ream and cerebral spinal fluid
@en
P2093
P2860
P356
P1476
A reference laboratory experie ...... ream and cerebral spinal fluid
@en
P2093
Annette W Fothergill
Deanna A Sutton
Gennethel J Pennick
James S Lewis
Sheryl A Dorsey
Thomas F Patterson
Wieslaw Furmaga
P2860
P304
P356
10.1128/AAC.01558-13
P407
P577
2013-11-04T00:00:00Z